[Which statin is more efficient? Concepts and applications in economic evaluation].
García-Altés
A
A
Agència d'Avaluació de Tecnologia Mèdica, Universitat Autònoma de Barcelona.
Jovell
A J
AJ
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage / Q000191:economics; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000191:economics*; D007211:Indoles / Q000008:administration & dosage / Q000191:economics; D008148:Lovastatin / Q000008:administration & dosage / Q000191:economics; D017035:Pravastatin / Q000008:administration & dosage / Q000191:economics; D019821:Simvastatin / Q000008:administration & dosage / Q000191:economics
D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007211:Indoles; D000077340:Fluvastatin; D008148:Lovastatin; D019821:Simvastatin; D017035:Pravastatin